HLA-B*1502 DETECTION-Individual Target Drug-Products-Guangzhou SaiWang Biological technology co., LTD

PRODUCT

Address: Huangpu district Science town, Guangzhou, Kaiyuan Dadao no.188, G building, room 405-406

Phone: 020-87658152

Fax: 020-87658152-803

Home > Products > Individual Target Drug > Article

HLA-B*1502 DETECTION

PG1502 Detection Kit

DETAILS

Relating to Drug: Carbamazepine & Phenytoin

HLA-B*1502 Detection
RT-PCR & SYBR Green based detection method: each sample requires only 2 PCR rxns for detecting of HLA-B*1502 and Internal Control. Analysis is based on Ct values. A complete kit version is CE marked and has IVD approval from Department of Health, Taiwan.

HLA-B*1502 Detection FastGel Test
PCR based detection method: each sample requires only 1 PCR rxn for detection of HLA-B*1502 and Internal Control. Analysis is based on gel electrophoresis or Agilent™ BioAnalyzer™.

Product Features

Required only hours from blood sample to results.
Designed for easy operation & analysis.
Validated accuracy with 4500+ patients samples* & DNA sequencing.
Protected by US, Europe & world wide patents.
Product Sheets available in right hand column.
Mix & Match design.

Regulatory Status
HLA-B*1502 Detection	HLA-B*1502 Detection FastGel Test
CE IVD	CE IVD
Taiwan IVD	Taiwan IVD
China IVD
US ASR

Many studies have demonstrated the strong association of Human Leukocyte Antigen (HLA-B*1502) and carbamazepine, phenytoin, & oxcarbazepine induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Individuals that use DNA tests to determine their HLA genotypes prior to taking these drugs can reduce their risks of developing SJS/TEN by as high as 1300 times.

Previous：HLA-B*5801 DETECTION

Next：No